These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 20444908)

  • 1. A pegylated growth hormone receptor antagonist, pegvisomant, does not enter the brain in humans.
    Veldhuis JD; Bidlingmaier M; Bailey J; Erickson D; Sandroni P
    J Clin Endocrinol Metab; 2010 Aug; 95(8):3844-7. PubMed ID: 20444908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lowering total plasma insulin-like growth factor I concentrations by way of a novel, potent, and selective growth hormone (GH) receptor antagonist, pegvisomant (B2036-peg), augments the amplitude of GH secretory bursts and elevates basal/nonpulsatile GH release in healthy women and men.
    Veldhuis JD; Bidlingmaier M; Anderson SM; Wu Z; Strasburger CJ
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3304-10. PubMed ID: 11443205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of experimental blockade of peripheral growth hormone (GH) receptors on the kinetics of endogenous and exogenous GH removal in healthy women and men.
    Veldhuis JD; Bidlingmaier M; Anderson SM; Evans WS; Wu Z; Strasburger CJ
    J Clin Endocrinol Metab; 2002 Dec; 87(12):5737-45. PubMed ID: 12466380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of fasting and pegvisomant on the GH-releasing hormone and GH-releasing peptide-6 stimulated growth hormone secretion.
    Muller AF; Janssen JA; Lamberts SW; Bidlingmaier M; Strasburger CJ; Hofland L; van der Lely AJ
    Clin Endocrinol (Oxf); 2001 Oct; 55(4):461-7. PubMed ID: 11678828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical pharmacodynamic effects of the growth hormone receptor antagonist pegvisomant: implications for cancer therapy.
    Yin D; Vreeland F; Schaaf LJ; Millham R; Duncan BA; Sharma A
    Clin Cancer Res; 2007 Feb; 13(3):1000-9. PubMed ID: 17289896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disease activity in acromegaly may be assessed 6 weeks after discontinuation of pegvisomant.
    Drake WM; Loureiro RA; Parkinson C; Monson JP; Besser GM; Trainer PJ
    Eur J Endocrinol; 2005 Jan; 152(1):47-51. PubMed ID: 15762186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor activity of the growth hormone receptor antagonist pegvisomant against human meningiomas in nude mice.
    McCutcheon IE; Flyvbjerg A; Hill H; Li J; Bennett WF; Scarlett JA; Friend KE
    J Neurosurg; 2001 Mar; 94(3):487-92. PubMed ID: 11235955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist.
    Jørgensen JO; Feldt-Rasmussen U; Frystyk J; Chen JW; Kristensen LØ; Hagen C; Ørskov H
    J Clin Endocrinol Metab; 2005 Oct; 90(10):5627-31. PubMed ID: 16046586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant.
    Sesmilo G; Fairfield WP; Katznelson L; Pulaski K; Freda PU; Bonert V; Dimaraki E; Stavrou S; Vance ML; Hayden D; Klibanski A
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1692-9. PubMed ID: 11932303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute effect of pegvisomant on cardiovascular risk markers in healthy men: implications for the pathogenesis of atherosclerosis in GH deficiency.
    Muller AF; Leebeek FW; Janssen JA; Lamberts SW; Hofland L; van der Lely AJ
    J Clin Endocrinol Metab; 2001 Nov; 86(11):5165-71. PubMed ID: 11701672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of pegvisomant treatment on substrate metabolism and insulin sensitivity in patients with acromegaly.
    Lindberg-Larsen R; Møller N; Schmitz O; Nielsen S; Andersen M; Orskov H; Jørgensen JO
    J Clin Endocrinol Metab; 2007 May; 92(5):1724-8. PubMed ID: 17341562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of a GH receptor antagonist (GHRA) to explore the relationship between GH and IGF-I in adults with severe GH deficiency (GHD).
    Berg CA; Pokrajac A; Bidlingmaier M; Strasburger CJ; Shalet SM; Trainer PJ
    Clin Endocrinol (Oxf); 2009 Mar; 70(3):439-45. PubMed ID: 19067728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Additional metabolic effects of adding GH receptor antagonist to long-acting somatostatin analog in patients with active acromegaly.
    Jawiarczyk A; Kałuzny M; Bolanowski M; Bednarek-Tupikowska G
    Neuro Endocrinol Lett; 2008 Aug; 29(4):571-6. PubMed ID: 18766168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pegvisomant in the treatment of acromegaly.
    Parkinson C; Scarlett JA; Trainer PJ
    Adv Drug Deliv Rev; 2003 Sep; 55(10):1303-14. PubMed ID: 14499709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The acute effect of a single application of cabergoline on endogenous GH levels in patients with acromegaly on pegvisomant treatment.
    Roemmler J; Steffin B; Gutt B; Schneider HJ; Sievers C; Bidlingmaier M; Schopohl J
    Growth Horm IGF Res; 2010 Oct; 20(5):338-44. PubMed ID: 20598600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pegvisomant: a growth hormone receptor antagonist used in the treatment of acromegaly.
    Tritos NA; Biller BM
    Pituitary; 2017 Feb; 20(1):129-135. PubMed ID: 27631335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma Agouti-Related Protein Levels in Acromegaly and Effects of Surgical or Pegvisomant Therapy.
    Freda PU; Reyes-Vidal C; Jin Z; Pugh M; Panigrahi SK; Bruce JN; Wardlaw SL
    J Clin Endocrinol Metab; 2019 Nov; 104(11):5453-5461. PubMed ID: 31361303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth.
    Divisova J; Kuiatse I; Lazard Z; Weiss H; Vreeland F; Hadsell DL; Schiff R; Osborne CK; Lee AV
    Breast Cancer Res Treat; 2006 Aug; 98(3):315-27. PubMed ID: 16541323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance.
    Colao A; Pivonello R; Auriemma RS; De Martino MC; Bidlingmaier M; Briganti F; Tortora F; Burman P; Kourides IA; Strasburger CJ; Lombardi G
    Eur J Endocrinol; 2006 Mar; 154(3):467-77. PubMed ID: 16498061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pegvisomant therapy in pituitary gigantism: successful treatment in a 12-year-old girl.
    Rix M; Laurberg P; Hoejberg AS; Brock-Jacobsen B
    Eur J Endocrinol; 2005 Aug; 153(2):195-201. PubMed ID: 16061823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.